Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | HK1 | P19367 | 2/20 | 0.36 |
| ▸ | HK2 | P52789 | 2/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407259 | 1.00 | SLC5A2 (0.42) | SLC5A2SLC5A1CYP11B1CYP11B2HK1 | |
| SCHEMBL3407879 | 0.92 | SLC5A2 (0.43) | SLC5A2SLC5A1CYP11B1CYP11B2SLC28A2 | |
| SCHEMBL6469217 | 0.92 | SLC5A2 (0.43) | SLC5A2SLC5A1CYP11B1CYP11B2SLC28A2 | |
| SCHEMBL3407888 | 0.90 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL3410072 | 0.90 | SLC5A2 (0.43) | SLC5A2SLC5A1 | |
| SCHEMBL3409061 | 0.90 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL3413663 | 0.90 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL6464664 | 0.88 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL4332311 | 0.88 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL3406498 | 0.88 | SLC5A2 (0.41) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | GANAB, GCG, GANC | SLC5A2 18/4885SLC5A1 19/4885CYP11B1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.